Liver Disease Risks

Addressing the Rise of Metabolic Dysfunction-Associated Steatotic Liver Disease: How Deerwood Family Practice Can Help

The rapid increase in obesity and metabolic syndrome across the U.S. is raising serious concerns about a condition known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease (NAFLD). This liver condition, which is not related to alcohol consumption, often presents with no symptoms in its early stages. As MASLD advances, it can lead to Metabolic Dysfunction-Associated Steatohepatitis (MASH), where harmful fat accumulates in the liver, potentially progressing to severe outcomes like fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) if left untreated.
With an estimated 100 million Americans currently living with MASLD and about 6.6 million at risk of developing liver fibrosis, it’s alarming to note that fewer than 5% of MASLD cases are accurately diagnosed. Early detection and management are crucial to prevent severe liver damage and improve patient outcomes.
At Deerwood Family Practice, we are committed to advancing liver health through innovative diagnostics. We are proud to offer the OWLiver® panel, a cutting-edge, non-invasive test designed to assess the stages of MASLD with precision. Unlike traditional tests that focus solely on abnormal liver enzymes, the OWLiver® panel evaluates 28 different liver metabolites and biomarkers. This comprehensive approach provides detailed insights into the amount of fat, level of inflammation, and extent of fibrosis in the liver.
The results include the MASEF Score, a highly specific, metabolomics-driven indicator that helps identify individuals at risk for MASH. Based on your unique results, we provide a range of tailored interventions to support liver health and promote natural detoxification. Our team is continually updating our knowledge through advanced education seminars on fatty liver disease to better serve our patients.

Sources:

Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, Muntané J, Pérez-Cormenzana M, García-Monzón C, Mayo R, Martín-Duce A, Romero-Gómez M, Lo Iacono O, Tordjman J, Andrade RJ, Pérez-Carreras M, Le Marchand-Brustel Y, Tran A, Fernández-Escalante C, Arévalo E, García-Unzueta M, Clement K, Crespo J, Gual P, Gómez-Fleitas M, Martínez-Chantar ML, Castro A, Lu SC, Vázquez-Chantada M, Mato JM. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res. 2012 Apr 6;11(4):2521-32. doi: 10.1021/pr201223p. Epub 2012 Mar 15. PMID: 22364559; PMCID: PMC3321123.

Mayo R, Crespo J, Martínez-Arranz I, Banales JM, Arias M, Mincholé I, Aller de la Fuente R, Jimenez-Agüero R, Alonso C, de Luis DA, Vitek L, Stritesky J, Caballería J, Romero-Gómez M, Martín-Duce A, Mugüerza Huguet JM, Busteros-Moraza JI, Idowu MO, Castro A, Martínez-Chantar ML, Ortiz P, Bruha R, Lu SC, Bedossa P, Noureddin M, Sanyal AJ, Mato JM. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatol Commun. 2018 May 4;2(7):807-820. doi: 10.1002/hep4.1188. PMID: 30027139; PMCID: PMC6049064.

. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi: 10.1097/ HEP.0000000000000323

Bril F, McPhaul MJ, Kalavalapalli S, et al. Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes. J Clin Endocrinol Metab. 2021;106(11):4360-e4371. doi: 10.1210/clinem/dgab417

Sarkar M, Yates K, Suzuki A, et al. Low testosterone is associated with nonalcoholic steatohepatitis and fibrosis severity in men. Clin Gastroenterol Hepatol. 2021;19(2):400-402.2. doi: 10.1016/j.cgh.2019.11.053

Kizivat T, Maric I, Mudri D, Curcic IB, Primorac D, Smolic M. Hypothyroidism and nonalcoholic fatty liver disease: pathophysiological associations and therapeutic implications. J Clin Transl Hepatol. 2020;8(3):347-
353. doi: 10.14218/JCTH.2020.00027